Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen

Keros Therapeutics (NASDAQ:KROS) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Sunday, Wall Street Zen reports.

Several other analysts have also issued reports on KROS. Leerink Partners reduced their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Wells Fargo & Company dropped their price target on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 4th. Zacks Research upgraded shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 27th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research report on Wednesday, August 12th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $20.50.

Keros Therapeutics Stock Down 2.5%

Shares of NASDAQ:KROS opened at $10.76 on Friday. The business’s 50 day moving average is $11.27 and its 200 day moving average is $12.10. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Analysts forecast that Keros Therapeutics will post -5.27 EPS for the current fiscal year.

Keros Therapeutics declared that its Board of Directors has authorized a stock repurchase plan on Wednesday, September 9th that permits the company to repurchase $5 million in shares. This buyback authorization permits the company to buy up to 2.3% of its shares through open market purchases. Share buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider directly owned 27,559 shares in the company, valued at $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock valued at $54,985 over the last three months. Company insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several large investors have recently added to or reduced their stakes in KROS. Legal & General Group Plc bought a new stake in Keros Therapeutics in the 2nd quarter valued at about $90,000. PDT Partners LLC purchased a new position in shares of Keros Therapeutics in the second quarter worth about $122,000. Lazard Asset Management LLC purchased a new position in shares of Keros Therapeutics in the first quarter worth about $129,000. Canada Pension Plan Investment Board bought a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $247,000. Finally, Quantinno Capital Management LP raised its position in shares of Keros Therapeutics by 12.5% in the first quarter. Quantinno Capital Management LP now owns 23,759 shares of the company’s stock valued at $262,000 after purchasing an additional 2,639 shares during the period. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.